A Mission for Making Good Medicine The University of Tennessee Research Foundation (UTRF), the University of Tennessee Health Science Center (UTHSC), and biotech therapeutics startup Anviron recently announced a partnership to commercialize a novel treatment with promising efficacy against pancreatic cancer tumors. According to the Genetic and Rare Diseases Information Center, the total number of (read more)
UTRF in the News
UTRF Licensee Announces Positive Phase 2 Clinical Results of VERU-111 for COVID-19
UTRF licensee Veru, Inc. announced today significant potential of VERU-111 in treating COVID-19, both as a broad-spectrum antiviral and an anti-inflammatory agent, which may help prevent effects leading to Acute Respiratory Distress Syndrome. Statistically significant data from the Phase 2 clinical study results show an 81% relative reduction in death or respiratory failure at Day (read more)
UTHSC Researchers Play Role in Supporting Development of COVID-19 Vaccines
To reduce the risk to workers developing and testing the COVID-19 vaccine, Pfizer-BioNTech and other companies have utilized a surrogate system, one of which was developed in the laboratory of Michael Whitt, PhD, a UTHSC virologist and UTRF innovator. Story written by Peggy Reisser, UTHSC Researchers at the University of Tennessee Health Science Center have (read more)